Latest Close
₹481.35
+0.44%
Connecting…
Day Range
-
Full OHLC pending
Volume
-
Full session data pending
50 DMA
₹448.32
200 DMA
₹415.43
1 year gain / loss
−₹297.60(-38.21%)
₹778.95 → ₹481.35· 2025-10-30 to 2026-10-30
Charting by TradingView
This stock does not satisfy the default swing-support rules at the selected chart endpoint. Its price, volume and moving averages remain available for manual research.
Snapshot 2026-11-01 · Financial period Jun 2026 · Consolidated figures where available
Cohance Lifesciences Limited, formerly Suven Pharmaceuticals Limited, is an India-based technology-driven contract development and manufacturing organization (CDMO), providing integrated solutions in custom synthesis, process research and development (R&D), and manufacturing. The Company’s business units include pharmaceutical CDMO, specialty chemical CDMO, and active pharmaceutical ingredient (API) (including formulations). Its integrated CDMO model enables comprehensive molecule development and life cycle management for both pharmaceutical and specialty chemical partners. Its custom synthesis services include design and synthesis, synthesis of complex molecules, synthesis of reference standards, synthesis of impurities and metabolites, scale-up of existing synthetic routes, and process optimization and backward integration. Its process research services include route scouting, process development, process safety evaluation, analytical method development, and regulatory support.
Market Cap
₹17,004.54 Cr
P/E
290.49×
Sector -38.72× · above
P/B
4.35×
Sector 4.11× · above
EV / EBITDA
53.04×
Sector 22.21× · above
ROE
5.05%
Sector 0.31%
ROCE
5.47%
Sector 6.48%
ROA
1.02%
Sector -17.12%
Cash Flow / Profit
2.45×
| Period | Revenue | Operating profit | Net profit |
|---|---|---|---|
| Jun 2026 | 434.51 -29.6% | -42.87 | -45.19 -643.8% |
| Mar 2026 | 617.28 +12.1% | 19.91 | 8.31 -71.4% |
| Dec 2025 | 550.71 -3.6% | 40.6 | 29.02 -56.3% |
| Sep 2025 | 571.17 | 83.77 | 66.39 |